Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 4/20 | 0.56 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6170749 | 0.86 | IMPDH2 (0.60) | IMPDH2IMPDH1MAP4K4NOTUMCYP3A4 | |
| SCHEMBL27330522 | 0.82 | NOTUM (0.56) | IMPDH2IMPDH1NOTUMCYP3A4TSHR | |
| SCHEMBL16238614 | 0.79 | IMPDH2 (0.56) | IMPDH2IMPDH1MAP4K4NOTUMCYP11B1 | |
| SCHEMBL22598718 | 0.79 | LMNA (0.53) | IMPDH2IMPDH1NOTUMCYP11B1CYP11B2 | |
| SCHEMBL12907859 | 0.79 | IMPDH2 (0.60) | IMPDH2IMPDH1MAP4K4NOTUMCYP3A4 | |
| SCHEMBL8347880 | 0.77 | IMPDH2 (0.62) | IMPDH2IMPDH1MAP4K4NOTUMTSHR | |
| SCHEMBL5780722 | 0.76 | IMPDH2 (0.60) | IMPDH2IMPDH1MAP4K4NOTUMCYP11B1 | |
| SCHEMBL6169923 | 0.76 | IMPDH2 (0.60) | IMPDH2IMPDH1MAP4K4NOTUMCYP11B1 | |
| SCHEMBL6168364 | 0.76 | IMPDH2 (0.65) | IMPDH2IMPDH1MAP4K4NOTUMCYP11B1 | |
| SCHEMBL29454983 | 0.76 | IMPDH2 (0.60) | IMPDH2IMPDH1MAP4K4NOTUMCYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3215510-B1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2023-06-07 | — | — | EP | disclosed |
| US-11400095-B2 | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2022-08-02 | — | — | US | disclosed |
| US-11351173-B2 | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2022-06-07 | — | — | US | disclosed |
| US-20210177853-A1 | SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2021-06-17 | — | — | US | disclosed |
| US-20210169886-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2021-06-10 | — | — | US | disclosed |
| US-10786508-B2 | Substituted imidazo[1,5-A]-pyrimidines and their use in the treatment of medical disorders | LYSOSOMAL THERAPEUTICS INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-10751341-B2 | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders | LYSOSOMAL THERAPEUTICS INC. (US) | 2020-08-25 | — | — | US | disclosed |
| EP-3215509-B1 | SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC (US) | 2020-02-26 | — | — | EP | disclosed |
| US-20200030331-A1 | SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2020-01-30 | — | — | US | disclosed |
| US-20190216813-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2019-07-18 | — | — | US | disclosed |
| US-20100113458-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-05-06 | — | — | US | disclosed |
| US-20100113458-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-05-06 | — | — | US | disclosed |
| US-20100113458-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-05-06 | — | — | US | disclosed |
| WO-2010042699-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010042699-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-15 | — | — | WO | disclosed |
| EP-1965805-B1 | UREA DERIVATIVES USEFUL AS CALCIUM RECEPTOR MODULATORS | GALAPAGOS SAS (FR) | 2009-12-02 | — | — | EP | disclosed |
| EP-1965805-A1 | UREA DERIVATIVES USEFUL AS CALCIUM RECEPTOR MODULATORS | Proskelia SAS (FR) | 2008-09-10 | — | — | EP | disclosed |
| US-20070179134-A1 | Urea derivatives, processes for their preparation, their use as medicaments, and pharmaceutical compositions containing them | PROSKELIA SAS. (FR) | 2007-08-02 | — | — | US | disclosed |
| WO-2007060026-A1 | UREA DERIVATIVES USEFUL AS CALCIUM RECEPTOR MODULATORS | GALAPAGOS SAS (FR) | 2007-05-31 | — | — | WO | disclosed |
| WO-2003040141-A1 | OXAZOLYL-PHENYL-2,4-DIAMINO-PYRIMIDINE COMPOUNDS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11351173-B2 | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders | TYMP, PARK7, PNP | IMPDH2 134/4885IMPDH1 100/4885MAP4K4 3027/4885 |
| US-20210177853-A1 | SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | TYMP, PARK7, PNP | IMPDH2 134/4885IMPDH1 100/4885MAP4K4 3027/4885 |
| US-20190216813-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, SNCA | IMPDH2 50/4885IMPDH1 31/4885MAP4K4 2393/4885 |
| US-10751341-B2 | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders | TYMP, PARK7, PNP | IMPDH2 134/4885IMPDH1 100/4885MAP4K4 3027/4885 |
| US-20200030331-A1 | SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | TYMP, PARK7, PNP | IMPDH2 134/4885IMPDH1 100/4885MAP4K4 3027/4885 |
| US-20210169886-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, SNCA | IMPDH2 50/4885IMPDH1 31/4885MAP4K4 2393/4885 |
| US-11400095-B2 | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders | GBA1, GAA, SNCA | IMPDH2 50/4885IMPDH1 31/4885MAP4K4 2393/4885 |
| US-20100113458-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | MAP3K5, MAP3K15, MAP4K2 | IMPDH2 460/4885IMPDH1 397/4885MAP4K4 17/4885 |
| US-20070179134-A1 | Urea derivatives, processes for their preparation, their use as medicaments, and pharmaceutical compositions containing them | UTS2R, CACNA1A, CACNA1E | IMPDH2 726/4885IMPDH1 635/4885MAP4K4 3483/4885 |
| US-10786508-B2 | Substituted imidazo[1,5-A]-pyrimidines and their use in the treatment of medical disorders | GBA1, GAA, SNCA | IMPDH2 53/4885IMPDH1 32/4885MAP4K4 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.